The cancer diagnostics market continues to be a hot space for investors, with San Francisco start-up Freenome Inc. recently securing $160m in funds to advance its multiomics blood-testing platform for early cancer detection.
The platform is being developed for use in multiple cancer types and is designed to detect key biological signals from a routine blood draw. It combines assays for cell-free DNA,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?